Medicare

ASRT CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed Against Assertio Holdings, Inc. (ASRT)

Retrieved on: 
Sunday, February 25, 2024

The action charges Assertio with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges Assertio with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of Assertio’ s materially misleading statements and omissions to the public, Assertio’ s investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages Assertio investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The class action complaint against Assertio, Shapiro v. Assertio Holdings, Inc., et al., Case No.

MBLY SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Mobileye Global Inc. (MBLY) Investors of Securities Fraud Class Action Lawsuit Filed On the Behalf

Retrieved on: 
Friday, February 23, 2024

The action charges Mobileye with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges Mobileye with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of Mobileye’s materially misleading statements and omissions to the public, Mobileye’ s investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages Mobileye investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The class action complaint against Mobileye, Mcauliffe v. Mobileye Global Inc., et al., Case No.

Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey

Retrieved on: 
Thursday, February 22, 2024

Spherix Global Insight’s January update from their Launch Dynamix™: Leqembi in Alzheimer’s Disease (US) service sheds light on neurologists’ early reactions to Leqembi.

Key Points: 
  • Spherix Global Insight’s January update from their Launch Dynamix™: Leqembi in Alzheimer’s Disease (US) service sheds light on neurologists’ early reactions to Leqembi.
  • Analysis from 75 high-prescribing U.S. neurologists reveals the potential reasons behind the even slower-than-expected adoption of Leqembi for treatment of early AD.
  • Six months after the full commercial launch of Leqembi, few surveyed neurologists consider Leqembi to be a significant medical advance over other historical AD treatments.
  • For all these reasons, Spherix will continue tracking neurologists’ attitudes and use of DMTs in AD well into the future.

Allsup Promotes Bethany Cissell To Director Of Business Development For Healthcare Insurance Services

Retrieved on: 
Thursday, February 22, 2024

Belleville, Illinois, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Allsup , a leader in disability representation and healthcare benefits services, proudly announces the promotion of Bethany Cissell to Director of Business Development for Healthcare Insurance Services (HIS).

Key Points: 
  • Belleville, Illinois, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Allsup , a leader in disability representation and healthcare benefits services, proudly announces the promotion of Bethany Cissell to Director of Business Development for Healthcare Insurance Services (HIS).
  • During her remarkable 13-year tenure with Allsup, Cissell has gained a wealth of experience.
  • Furthermore, Cissell has made significant contributions to the Allsup Benefits Coordination (ABC) service line, previously known as the Allsup Medicare Advisor (AMA) service.
  • As a recognized Medicare expert and seasoned media spokesperson, Cissell has been instrumental in the advancement of ABC services, positioning Allsup as a trusted leader in healthcare benefits.

GoHealth to Announce Fourth Quarter and Year End 2023 Results on March 14, 2024

Retrieved on: 
Thursday, February 22, 2024

CHICAGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- GoHealth, Inc. (GoHealth) (NASDAQ: GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced that the company will release its fourth quarter and full year 2023 financial results on the morning of March 14, 2024.

Key Points: 
  • CHICAGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- GoHealth, Inc. (GoHealth) (NASDAQ: GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced that the company will release its fourth quarter and full year 2023 financial results on the morning of March 14, 2024.
  • Chief Executive Officer, Vijay Kotte, and Chief Financial Officer, Jason Schulz, will host a conference call and live audio webcast on the day of the release at 8:00 a.m. (ET) to discuss the results.
  • A live audio webcast of the conference call will be available via GoHealth's Investor Relations website, https://investors.gohealth.com/ .
  • A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call.

BNTX Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds BioNTech SE (BNTX) Investors of Securities Fraud Class Action Lawsuit

Retrieved on: 
Thursday, February 22, 2024

RADNOR, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).

Key Points: 
  • RADNOR, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against BioNTech SE (“BioNTech”) ( NASDAQ: BNTX ).
  • The action charges BioNTech with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of BioNTech’ s materially misleading statements and omissions to the public, BioNTech’ s investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages BioNTech investors who have suffered significant losses to contact the firm directly to acquire more information.

AssureCare Revolutionizes Pharmacist Credentialing with Groundbreaking Solution

Retrieved on: 
Thursday, February 22, 2024

Health systems and clinics benefit from a credentialing department, AssureCare now enables community pharmacists to have the same capability through its AssureRx platform.

Key Points: 
  • Health systems and clinics benefit from a credentialing department, AssureCare now enables community pharmacists to have the same capability through its AssureRx platform.
  • AssureCare introduces a new AssureRx solution designed to navigate the intricacies of pharmacist credentialing with unparalleled expertise.
  • The combined impact of AssureRx’s innovative credentialing platform, pharmacy professionals, and credentialing specialists will help pharmacists prepare their pharmacy for the future.
  • “We understand the challenges pharmacist providers face in navigating the credentialing landscape,” states Tara Pfund, PharmD at AssureCare, “and we want to help relieve that burden and advocate for change.” AssureRx is committed to revolutionizing the pharmacist credentialing process, providing a one-stop solution for professionals seeking integration into medical plans.

NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights

Retrieved on: 
Thursday, February 22, 2024

WOBURN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023.

Key Points: 
  • WOBURN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023.
  • "Quell® Fibromyalgia growth accelerated in Q4 2023 reflecting the addition in Q3 2023 of two field business development managers and optimized clinical messaging.
  • In the successive quarters of Q4 2023 versus Q3 2023, all key operating metrics showed substantial growth.
  • The Q4 2023 net loss was $1.6 million ($1.43 per share) versus a net loss of $0.7 million ($0.73 per share) in Q4 2022.

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against Amplitude, Inc. (AMPL) and Encourages Investors with Significant Losses to Contact the Firm

Retrieved on: 
Wednesday, February 21, 2024

The action charges Amplitude with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges Amplitude with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of Amplitude’ s materially misleading statements and omissions to the public, Amplitude’s investors have suffered significant losses.
  • Our securities fraud litigators are regularly recognized as leaders in the field as well as the firm itself which is continuously awarded for the successful results we’ve achieved.
  • Kessler Topaz Meltzer & Check, LLP encourages Amplitude investors who have suffered significant losses to contact the firm directly to acquire more information.

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 20, 2024

Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.

Key Points: 
  • Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.
  • Total costs of revenue were $7.4 million and $26.1 million for the fourth quarter and full year of 2023, respectively.
  • Approximately 84,000 prescriptions were written for Auvelity in the fourth quarter of 2023, representing a 23% sequential increase versus the third quarter of 2023.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss fourth quarter and full year 2023 financial results as well as to provide a corporate update.